The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Phase II study of fixed-duration obinutuzumab, ibrutinib & venetoclax in elderly patients with RT
Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, comments on recent developments in the treatment of elderly patients with Richter’s transformation (RT), sharing results from a Phase II trial (NCT04939363) using an experimental regimen consisting of fixed-duration obinutuzumab, ibrutinib, and venetoclax. Dr Tadmor highlights the study’s unique elderly cohort, with a median age of 76, in addition to the rapid ramp-up of venetoclax introduction, and further summarizes key results. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
